Rotavirus immunization: Global coverage and local barriers for implementation
Abstract Background Rotavirus (RV) is a major agent of gastroenteritis and an important cause of child death worldwide. Immunization (RVI) has been available since 2006, and the Federation of International Societies of Gastroenterology Hepatology and Nutrition (FISPGHAN) identified RVI as a top prio...
Gespeichert in:
Veröffentlicht in: | Vaccine 2017-03, Vol.35 (12), p.1637-1644 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1644 |
---|---|
container_issue | 12 |
container_start_page | 1637 |
container_title | Vaccine |
container_volume | 35 |
creator | Lo Vecchio, Andrea Liguoro, Ilaria Dias, Jorge Amil Berkley, James A Boey, Chris Cohen, Mitchell B Cruchet, Sylvia Salazar-Lindo, Eduardo Podder, Samir Sandhu, Bhupinder Sherman, Philip M Shimizu, Toshiaki Guarino, Alfredo |
description | Abstract Background Rotavirus (RV) is a major agent of gastroenteritis and an important cause of child death worldwide. Immunization (RVI) has been available since 2006, and the Federation of International Societies of Gastroenterology Hepatology and Nutrition (FISPGHAN) identified RVI as a top priority for the control of diarrheal illness. A FISPGHAN working group on acute diarrhea aimed at estimating the current RVI coverage worldwide and identifying barriers to implementation at local level. Methods A survey was distributed to national experts in infectious diseases and health-care authorities (March 2015–April 2016), collecting information on local recommendations, costs and perception of barriers for implementation. Results Forty-nine of the 79 contacted countries (62% response rate) provided a complete analyzable data. RVI was recommended in 27/49 countries (55%). Although five countries have recommended RVI since 2006, a large number (16, 33%) included RVI in a National Immunization Schedule between 2012 and 2014. The costs of vaccination are covered by the government (39%), by the GAVI Alliance (10%) or public and private insurance (8%) in some countries. However, in most cases, immunization is paid by families (43%). Elevated cost of vaccine (49%) is the main barrier for implementation of RVI. High costs of vaccination (rs = −0.39, p = 0.02) and coverage of expenses by families (rs = 0.5, p = 0.002) significantly correlate with a lower immunization rate. Limited perception of RV illness severity by the families (47%), public-health authorities (37%) or physicians (24%) and the timing of administration (16%) are further major barriers to large- scale RVI programs. Conclusions After 10 years since its introduction, the implementation of RVI is still unacceptably low and should remain a major target for global public health. Barriers to implementation vary according to setting. Nevertheless, public health authorities should promote education for caregivers and health-care providers and interact with local health authorities in order to implement RVI. |
doi_str_mv | 10.1016/j.vaccine.2017.01.082 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6624129</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X17301627</els_id><sourcerecordid>4318849711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c682t-550aece88067cc2b8bbf0acaba7561c8949caf59d1b6fd6d12cb5cf7701e4cb83</originalsourceid><addsrcrecordid>eNqNkk9v1DAQxSMEokvhI4AiceGS4HES2-FQhCooSEVI_JG4Wc5kUrwk8WInkcqnx-kuBXopJ0v27z1r3rwkeQwsBwbi-TZfDKIdKecMZM4gZ4rfSTagZJHxCtTdZMO4KLMS2Nej5EEIW8ZYVUB9PzniioMAVW-S9x_dZBbr55DaYZhH-9NM1o0v0rPeNaZP0S3kzQWlZmzT3mG8aoz3lnxIO-ejaNfTQON0JXuY3OtMH-jR4TxOvrx5_fn0bXb-4ezd6avzDIXiU1ZVzBCSUkxIRN6opumYQdMYWQlAVZc1mq6qW2hE14oWODYVdlIyoBIbVRwnJ3vf3dwM1GL835te77wdjL_Uzlj978tov-kLt2gheAm8jgbPDgbe_ZgpTHqwAanvzUhuDprHrLhSBahb0Ri4VGUNUv4PykTcBxQRfXoD3brZjzG0lSrLmMMVVe0p9C4ET931iMD0WgO91Yca6LUGmoGONYi6J3_nc636vfcIvNwDFLe0xG3qgJZGpNZ6wkm3zt76xckNB-ztaGNBvtMlhT_T6MA105_WLq5VBFlEUy6LX2Fn3IY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1874456113</pqid></control><display><type>article</type><title>Rotavirus immunization: Global coverage and local barriers for implementation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Lo Vecchio, Andrea ; Liguoro, Ilaria ; Dias, Jorge Amil ; Berkley, James A ; Boey, Chris ; Cohen, Mitchell B ; Cruchet, Sylvia ; Salazar-Lindo, Eduardo ; Podder, Samir ; Sandhu, Bhupinder ; Sherman, Philip M ; Shimizu, Toshiaki ; Guarino, Alfredo</creator><creatorcontrib>Lo Vecchio, Andrea ; Liguoro, Ilaria ; Dias, Jorge Amil ; Berkley, James A ; Boey, Chris ; Cohen, Mitchell B ; Cruchet, Sylvia ; Salazar-Lindo, Eduardo ; Podder, Samir ; Sandhu, Bhupinder ; Sherman, Philip M ; Shimizu, Toshiaki ; Guarino, Alfredo</creatorcontrib><description>Abstract Background Rotavirus (RV) is a major agent of gastroenteritis and an important cause of child death worldwide. Immunization (RVI) has been available since 2006, and the Federation of International Societies of Gastroenterology Hepatology and Nutrition (FISPGHAN) identified RVI as a top priority for the control of diarrheal illness. A FISPGHAN working group on acute diarrhea aimed at estimating the current RVI coverage worldwide and identifying barriers to implementation at local level. Methods A survey was distributed to national experts in infectious diseases and health-care authorities (March 2015–April 2016), collecting information on local recommendations, costs and perception of barriers for implementation. Results Forty-nine of the 79 contacted countries (62% response rate) provided a complete analyzable data. RVI was recommended in 27/49 countries (55%). Although five countries have recommended RVI since 2006, a large number (16, 33%) included RVI in a National Immunization Schedule between 2012 and 2014. The costs of vaccination are covered by the government (39%), by the GAVI Alliance (10%) or public and private insurance (8%) in some countries. However, in most cases, immunization is paid by families (43%). Elevated cost of vaccine (49%) is the main barrier for implementation of RVI. High costs of vaccination (rs = −0.39, p = 0.02) and coverage of expenses by families (rs = 0.5, p = 0.002) significantly correlate with a lower immunization rate. Limited perception of RV illness severity by the families (47%), public-health authorities (37%) or physicians (24%) and the timing of administration (16%) are further major barriers to large- scale RVI programs. Conclusions After 10 years since its introduction, the implementation of RVI is still unacceptably low and should remain a major target for global public health. Barriers to implementation vary according to setting. Nevertheless, public health authorities should promote education for caregivers and health-care providers and interact with local health authorities in order to implement RVI.</description><identifier>ISSN: 0264-410X</identifier><identifier>ISSN: 1873-2518</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2017.01.082</identifier><identifier>PMID: 28216189</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Allergy and Immunology ; caregivers ; children ; death ; Diarrhea ; education ; Experts ; Fatalities ; Gastroenteritis ; Gastroenteritis - epidemiology ; Gastroenteritis - prevention & control ; Gastroenterology ; Global Health ; Health care ; health services ; Hepatology ; Humans ; Immunization ; Implementation ; Infectious diseases ; insurance ; Pediatrics ; physicians ; Public health ; Reoviridae ; Rotavirus ; Rotavirus Infections - epidemiology ; Rotavirus Infections - prevention & control ; Rotavirus Vaccines - administration & dosage ; Rotavirus Vaccines - immunology ; surveys ; Surveys and Questionnaires ; vaccination ; Vaccination Coverage ; Vaccine ; Vaccines ; Variance analysis ; Viruses ; Working groups</subject><ispartof>Vaccine, 2017-03, Vol.35 (12), p.1637-1644</ispartof><rights>Elsevier Ltd</rights><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Mar 14, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c682t-550aece88067cc2b8bbf0acaba7561c8949caf59d1b6fd6d12cb5cf7701e4cb83</citedby><cites>FETCH-LOGICAL-c682t-550aece88067cc2b8bbf0acaba7561c8949caf59d1b6fd6d12cb5cf7701e4cb83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X17301627$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28216189$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lo Vecchio, Andrea</creatorcontrib><creatorcontrib>Liguoro, Ilaria</creatorcontrib><creatorcontrib>Dias, Jorge Amil</creatorcontrib><creatorcontrib>Berkley, James A</creatorcontrib><creatorcontrib>Boey, Chris</creatorcontrib><creatorcontrib>Cohen, Mitchell B</creatorcontrib><creatorcontrib>Cruchet, Sylvia</creatorcontrib><creatorcontrib>Salazar-Lindo, Eduardo</creatorcontrib><creatorcontrib>Podder, Samir</creatorcontrib><creatorcontrib>Sandhu, Bhupinder</creatorcontrib><creatorcontrib>Sherman, Philip M</creatorcontrib><creatorcontrib>Shimizu, Toshiaki</creatorcontrib><creatorcontrib>Guarino, Alfredo</creatorcontrib><title>Rotavirus immunization: Global coverage and local barriers for implementation</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Background Rotavirus (RV) is a major agent of gastroenteritis and an important cause of child death worldwide. Immunization (RVI) has been available since 2006, and the Federation of International Societies of Gastroenterology Hepatology and Nutrition (FISPGHAN) identified RVI as a top priority for the control of diarrheal illness. A FISPGHAN working group on acute diarrhea aimed at estimating the current RVI coverage worldwide and identifying barriers to implementation at local level. Methods A survey was distributed to national experts in infectious diseases and health-care authorities (March 2015–April 2016), collecting information on local recommendations, costs and perception of barriers for implementation. Results Forty-nine of the 79 contacted countries (62% response rate) provided a complete analyzable data. RVI was recommended in 27/49 countries (55%). Although five countries have recommended RVI since 2006, a large number (16, 33%) included RVI in a National Immunization Schedule between 2012 and 2014. The costs of vaccination are covered by the government (39%), by the GAVI Alliance (10%) or public and private insurance (8%) in some countries. However, in most cases, immunization is paid by families (43%). Elevated cost of vaccine (49%) is the main barrier for implementation of RVI. High costs of vaccination (rs = −0.39, p = 0.02) and coverage of expenses by families (rs = 0.5, p = 0.002) significantly correlate with a lower immunization rate. Limited perception of RV illness severity by the families (47%), public-health authorities (37%) or physicians (24%) and the timing of administration (16%) are further major barriers to large- scale RVI programs. Conclusions After 10 years since its introduction, the implementation of RVI is still unacceptably low and should remain a major target for global public health. Barriers to implementation vary according to setting. Nevertheless, public health authorities should promote education for caregivers and health-care providers and interact with local health authorities in order to implement RVI.</description><subject>Age</subject><subject>Allergy and Immunology</subject><subject>caregivers</subject><subject>children</subject><subject>death</subject><subject>Diarrhea</subject><subject>education</subject><subject>Experts</subject><subject>Fatalities</subject><subject>Gastroenteritis</subject><subject>Gastroenteritis - epidemiology</subject><subject>Gastroenteritis - prevention & control</subject><subject>Gastroenterology</subject><subject>Global Health</subject><subject>Health care</subject><subject>health services</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Immunization</subject><subject>Implementation</subject><subject>Infectious diseases</subject><subject>insurance</subject><subject>Pediatrics</subject><subject>physicians</subject><subject>Public health</subject><subject>Reoviridae</subject><subject>Rotavirus</subject><subject>Rotavirus Infections - epidemiology</subject><subject>Rotavirus Infections - prevention & control</subject><subject>Rotavirus Vaccines - administration & dosage</subject><subject>Rotavirus Vaccines - immunology</subject><subject>surveys</subject><subject>Surveys and Questionnaires</subject><subject>vaccination</subject><subject>Vaccination Coverage</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Variance analysis</subject><subject>Viruses</subject><subject>Working groups</subject><issn>0264-410X</issn><issn>1873-2518</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkk9v1DAQxSMEokvhI4AiceGS4HES2-FQhCooSEVI_JG4Wc5kUrwk8WInkcqnx-kuBXopJ0v27z1r3rwkeQwsBwbi-TZfDKIdKecMZM4gZ4rfSTagZJHxCtTdZMO4KLMS2Nej5EEIW8ZYVUB9PzniioMAVW-S9x_dZBbr55DaYZhH-9NM1o0v0rPeNaZP0S3kzQWlZmzT3mG8aoz3lnxIO-ejaNfTQON0JXuY3OtMH-jR4TxOvrx5_fn0bXb-4ezd6avzDIXiU1ZVzBCSUkxIRN6opumYQdMYWQlAVZc1mq6qW2hE14oWODYVdlIyoBIbVRwnJ3vf3dwM1GL835te77wdjL_Uzlj978tov-kLt2gheAm8jgbPDgbe_ZgpTHqwAanvzUhuDprHrLhSBahb0Ri4VGUNUv4PykTcBxQRfXoD3brZjzG0lSrLmMMVVe0p9C4ET931iMD0WgO91Yca6LUGmoGONYi6J3_nc636vfcIvNwDFLe0xG3qgJZGpNZ6wkm3zt76xckNB-ztaGNBvtMlhT_T6MA105_WLq5VBFlEUy6LX2Fn3IY</recordid><startdate>20170314</startdate><enddate>20170314</enddate><creator>Lo Vecchio, Andrea</creator><creator>Liguoro, Ilaria</creator><creator>Dias, Jorge Amil</creator><creator>Berkley, James A</creator><creator>Boey, Chris</creator><creator>Cohen, Mitchell B</creator><creator>Cruchet, Sylvia</creator><creator>Salazar-Lindo, Eduardo</creator><creator>Podder, Samir</creator><creator>Sandhu, Bhupinder</creator><creator>Sherman, Philip M</creator><creator>Shimizu, Toshiaki</creator><creator>Guarino, Alfredo</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7U2</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20170314</creationdate><title>Rotavirus immunization: Global coverage and local barriers for implementation</title><author>Lo Vecchio, Andrea ; Liguoro, Ilaria ; Dias, Jorge Amil ; Berkley, James A ; Boey, Chris ; Cohen, Mitchell B ; Cruchet, Sylvia ; Salazar-Lindo, Eduardo ; Podder, Samir ; Sandhu, Bhupinder ; Sherman, Philip M ; Shimizu, Toshiaki ; Guarino, Alfredo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c682t-550aece88067cc2b8bbf0acaba7561c8949caf59d1b6fd6d12cb5cf7701e4cb83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Age</topic><topic>Allergy and Immunology</topic><topic>caregivers</topic><topic>children</topic><topic>death</topic><topic>Diarrhea</topic><topic>education</topic><topic>Experts</topic><topic>Fatalities</topic><topic>Gastroenteritis</topic><topic>Gastroenteritis - epidemiology</topic><topic>Gastroenteritis - prevention & control</topic><topic>Gastroenterology</topic><topic>Global Health</topic><topic>Health care</topic><topic>health services</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Immunization</topic><topic>Implementation</topic><topic>Infectious diseases</topic><topic>insurance</topic><topic>Pediatrics</topic><topic>physicians</topic><topic>Public health</topic><topic>Reoviridae</topic><topic>Rotavirus</topic><topic>Rotavirus Infections - epidemiology</topic><topic>Rotavirus Infections - prevention & control</topic><topic>Rotavirus Vaccines - administration & dosage</topic><topic>Rotavirus Vaccines - immunology</topic><topic>surveys</topic><topic>Surveys and Questionnaires</topic><topic>vaccination</topic><topic>Vaccination Coverage</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Variance analysis</topic><topic>Viruses</topic><topic>Working groups</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lo Vecchio, Andrea</creatorcontrib><creatorcontrib>Liguoro, Ilaria</creatorcontrib><creatorcontrib>Dias, Jorge Amil</creatorcontrib><creatorcontrib>Berkley, James A</creatorcontrib><creatorcontrib>Boey, Chris</creatorcontrib><creatorcontrib>Cohen, Mitchell B</creatorcontrib><creatorcontrib>Cruchet, Sylvia</creatorcontrib><creatorcontrib>Salazar-Lindo, Eduardo</creatorcontrib><creatorcontrib>Podder, Samir</creatorcontrib><creatorcontrib>Sandhu, Bhupinder</creatorcontrib><creatorcontrib>Sherman, Philip M</creatorcontrib><creatorcontrib>Shimizu, Toshiaki</creatorcontrib><creatorcontrib>Guarino, Alfredo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Safety Science and Risk</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lo Vecchio, Andrea</au><au>Liguoro, Ilaria</au><au>Dias, Jorge Amil</au><au>Berkley, James A</au><au>Boey, Chris</au><au>Cohen, Mitchell B</au><au>Cruchet, Sylvia</au><au>Salazar-Lindo, Eduardo</au><au>Podder, Samir</au><au>Sandhu, Bhupinder</au><au>Sherman, Philip M</au><au>Shimizu, Toshiaki</au><au>Guarino, Alfredo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rotavirus immunization: Global coverage and local barriers for implementation</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2017-03-14</date><risdate>2017</risdate><volume>35</volume><issue>12</issue><spage>1637</spage><epage>1644</epage><pages>1637-1644</pages><issn>0264-410X</issn><issn>1873-2518</issn><eissn>1873-2518</eissn><abstract>Abstract Background Rotavirus (RV) is a major agent of gastroenteritis and an important cause of child death worldwide. Immunization (RVI) has been available since 2006, and the Federation of International Societies of Gastroenterology Hepatology and Nutrition (FISPGHAN) identified RVI as a top priority for the control of diarrheal illness. A FISPGHAN working group on acute diarrhea aimed at estimating the current RVI coverage worldwide and identifying barriers to implementation at local level. Methods A survey was distributed to national experts in infectious diseases and health-care authorities (March 2015–April 2016), collecting information on local recommendations, costs and perception of barriers for implementation. Results Forty-nine of the 79 contacted countries (62% response rate) provided a complete analyzable data. RVI was recommended in 27/49 countries (55%). Although five countries have recommended RVI since 2006, a large number (16, 33%) included RVI in a National Immunization Schedule between 2012 and 2014. The costs of vaccination are covered by the government (39%), by the GAVI Alliance (10%) or public and private insurance (8%) in some countries. However, in most cases, immunization is paid by families (43%). Elevated cost of vaccine (49%) is the main barrier for implementation of RVI. High costs of vaccination (rs = −0.39, p = 0.02) and coverage of expenses by families (rs = 0.5, p = 0.002) significantly correlate with a lower immunization rate. Limited perception of RV illness severity by the families (47%), public-health authorities (37%) or physicians (24%) and the timing of administration (16%) are further major barriers to large- scale RVI programs. Conclusions After 10 years since its introduction, the implementation of RVI is still unacceptably low and should remain a major target for global public health. Barriers to implementation vary according to setting. Nevertheless, public health authorities should promote education for caregivers and health-care providers and interact with local health authorities in order to implement RVI.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>28216189</pmid><doi>10.1016/j.vaccine.2017.01.082</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0264-410X |
ispartof | Vaccine, 2017-03, Vol.35 (12), p.1637-1644 |
issn | 0264-410X 1873-2518 1873-2518 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6624129 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Age Allergy and Immunology caregivers children death Diarrhea education Experts Fatalities Gastroenteritis Gastroenteritis - epidemiology Gastroenteritis - prevention & control Gastroenterology Global Health Health care health services Hepatology Humans Immunization Implementation Infectious diseases insurance Pediatrics physicians Public health Reoviridae Rotavirus Rotavirus Infections - epidemiology Rotavirus Infections - prevention & control Rotavirus Vaccines - administration & dosage Rotavirus Vaccines - immunology surveys Surveys and Questionnaires vaccination Vaccination Coverage Vaccine Vaccines Variance analysis Viruses Working groups |
title | Rotavirus immunization: Global coverage and local barriers for implementation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A39%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rotavirus%20immunization:%20Global%20coverage%20and%20local%20barriers%20for%20implementation&rft.jtitle=Vaccine&rft.au=Lo%20Vecchio,%20Andrea&rft.date=2017-03-14&rft.volume=35&rft.issue=12&rft.spage=1637&rft.epage=1644&rft.pages=1637-1644&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2017.01.082&rft_dat=%3Cproquest_pubme%3E4318849711%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1874456113&rft_id=info:pmid/28216189&rft_els_id=S0264410X17301627&rfr_iscdi=true |